(Reuters) - LOS ANGELES, July 19 - Biotechnology company Gilead Sciences Inc. said on Thursday its second-quarter profit rose 54 percent on strong demand for its drugs that combat HIV, the virus that causes AIDS.
The maker of Truvada and Atripla, which combine anti-HIV drugs into a single pill, posted net income of $407.9 million, or 42 cents per share, compared to a profit of $265.2 million, or 28 cents per share, a year earlier.
Read more at Reuters.com Market News
The maker of Truvada and Atripla, which combine anti-HIV drugs into a single pill, posted net income of $407.9 million, or 42 cents per share, compared to a profit of $265.2 million, or 28 cents per share, a year earlier.
Read more at Reuters.com Market News
No comments:
Post a Comment